Alaunos Therapeutics, Inc. announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 October 1, 2022. Details of the presentation are as follows: Title: Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced Non-small cell lung cancer; Presenter: Marcelo V. Negrao, MD, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center; Date and Time:Friday, September 30, 2022, 8:30am ET; Session Title: Session 6: Cellular Therapies: Engineering T cells.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | +1.83% | -3.48% | +4.67% |
1st Jan change | Capi. | |
---|---|---|
+4.67% | 17.77M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+0.79% | 22.48B | |
-9.65% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference